902 related articles for article (PubMed ID: 30858549)
21. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.
Kumar SK; Dimopoulos MA; Kastritis E; Terpos E; Nahi H; Goldschmidt H; Hillengass J; Leleu X; Beksac M; Alsina M; Oriol A; Cavo M; Ocio EM; Mateos MV; O'Donnell EK; Vij R; Lokhorst HM; van de Donk NWCJ; Min C; Mark T; Turesson I; Hansson M; Ludwig H; Jagannath S; Delforge M; Kyriakou C; Hari P; Mellqvist U; Usmani SZ; Dytfeld D; Badros AZ; Moreau P; Kim K; Otero PR; Lee JH; Shustik C; Waller D; Chng WJ; Ozaki S; Lee JJ; de la Rubia J; Eom HS; Rosinol L; Lahuerta JJ; Sureda A; Kim JS; Durie BGM
Leukemia; 2017 Nov; 31(11):2443-2448. PubMed ID: 28620163
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
[TBL] [Abstract][Full Text] [Related]
23. Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
Alici E; Chrobok M; Lund J; Ahmadi T; Khan I; Duru AD; Nahi H
Br J Haematol; 2016 Aug; 174(3):473-7. PubMed ID: 26455823
[No Abstract] [Full Text] [Related]
24. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K
Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864
[TBL] [Abstract][Full Text] [Related]
26. [CD38 antibodies in multiple myeloma].
Moreaux J
Med Sci (Paris); 2019 Dec; 35(12):1001-1004. PubMed ID: 31903907
[TBL] [Abstract][Full Text] [Related]
27. Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort.
Maouche N; Srinivasan A; Leary H; Collings F; Tseu B; Vallance GD; Ramasamy K; Kothari J
J Oncol Pharm Pract; 2023 Mar; 29(2):299-304. PubMed ID: 34939868
[TBL] [Abstract][Full Text] [Related]
28. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK
Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602
[TBL] [Abstract][Full Text] [Related]
29. CD38 as an immunotherapeutic target in multiple myeloma.
Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
[TBL] [Abstract][Full Text] [Related]
30. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
[No Abstract] [Full Text] [Related]
31. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
[TBL] [Abstract][Full Text] [Related]
32. The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
Shallis RM; Terry CM; Lim SH
Cancer Immunol Immunother; 2017 Jun; 66(6):697-703. PubMed ID: 28341874
[TBL] [Abstract][Full Text] [Related]
33. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Krejcik J; Casneuf T; Nijhof IS; Verbist B; Bald J; Plesner T; Syed K; Liu K; van de Donk NW; Weiss BM; Ahmadi T; Lokhorst HM; Mutis T; Sasser AK
Blood; 2016 Jul; 128(3):384-94. PubMed ID: 27222480
[TBL] [Abstract][Full Text] [Related]
34. Current antibody-based therapies for the treatment of multiple myeloma.
Varga C; Waldschmidt JM; Gandolfi S; Richardson PG
Clin Adv Hematol Oncol; 2020 Nov; 18(11):736-748. PubMed ID: 33406065
[TBL] [Abstract][Full Text] [Related]
35. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
36. Editorial: Immunotherapy in Multiple Myeloma.
Giuliani N; Malavasi F
Front Immunol; 2019; 10():1945. PubMed ID: 31475006
[No Abstract] [Full Text] [Related]
37. [Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma].
Tamura H
Rinsho Ketsueki; 2018; 59(10):2169-2177. PubMed ID: 30305523
[TBL] [Abstract][Full Text] [Related]
38. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
39. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
40. Targeting NAD
Kennedy BE; Sadek M; Elnenaei MO; Reiman A; Gujar SA
Trends Cancer; 2020 Jan; 6(1):9-12. PubMed ID: 31952784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
